RxDoctor Payments DataLook up a doctor →

Adam Gadzinski, MD

Urology · Royal Oak, MINPI 1659613396

Payments from drug & device makers

$726,645in general payments, 2019–2025

Across 248 payments — averaging $2930.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$370K
  • Janssen Research & Development, LLC$291K
  • Sumitomo Pharma America, Inc.$30K
  • Novartis$17K
  • Pfizer$5K
  • Urogen Pharma, Inc.$3K
  • plus $10K from 35 others

What the payments were for

  • Consulting fees$10,02546%
  • Speaking & faculty fees$2,50011%
  • Travel & lodging$2,57212%
  • Food & beverage$5,01323%
  • Education$1,7238%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$726,645 in reported general payments places this provider in the 95th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$388,224
Medicare patients
445
Services billed
6,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide23$288,246
XtandiEnzalutamide11$158,935
Abiraterone Acetate36$66,035
OrgovyxRelugolix16$40,103
GemtesaVibegron46$26,361
MyrbetriqMirabegron18$13,972
Tamsulosin Hcl287$5,420
Potassium Citrate ErPotassium Citrate27$3,044
Dutasteride55$2,195
Finasteride61$1,057
Tadalafil13$951
Alfuzosin Hcl ErAlfuzosin Hcl25$931
Solifenacin Succinate21$878
Oxybutynin Chloride ErOxybutynin Chloride13$309
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$50$288,24623 claims
Astellas Pharma US IncXtandi, Myrbetriq$342$172,90729 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$30,232$66,46462 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,770$66,03536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 urology providers in Michigan.

Other urology in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →